MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
62.92
+4.60 (7.89%)
At close: Jul 17, 2026, 4:00 PM EDT
63.98
+1.06 (1.69%)
After-hours: Jul 17, 2026, 7:56 PM EDT
MBX Biosciences Employees
MBX Biosciences had 63 employees as of December 31, 2025. The number of employees increased by 20 or 46.51% compared to the previous year.
Employees
63
Change (1Y)
20
Growth (1Y)
46.51%
Revenue / Employee
n/a
Profits / Employee
-$1,374,730
Market Cap
2.99B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 63 | 20 | 46.51% |
| Dec 31, 2024 | 43 | 16 | 59.26% |
| Sep 30, 2024 | 38 | 11 | 40.74% |
| Jun 30, 2024 | 36 | - | - |
| Mar 31, 2024 | 28 | - | - |
| Dec 31, 2023 | 27 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Beam Therapeutics | 522 |
| Tarsus Pharmaceuticals | 370 |
| Vera Therapeutics | 339 |
| uniQure | 221 |
| Immunome | 206 |
| Celldex Therapeutics | 198 |
| Disc Medicine | 154 |
MBX News
- 4 days ago - MBX Biosciences CEO Kent Hawryluk steps down, Steve Hoerter succeeds - TheFly
- 4 days ago - MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth - GlobeNewsWire
- 5 weeks ago - MBX Biosciences down 19% at $30.05 after announcing canvuparatide study results - TheFly
- 5 weeks ago - MBX Biosciences Transcript: Study result - Transcripts
- 5 weeks ago - MBX Biosciences Slides: Study result - Filings
- 5 weeks ago - MBX Biosciences Press release: Study result - Filings
- 5 weeks ago - MBX Biosciences announces results from Avail, canvuparatide trials - TheFly
- 5 weeks ago - MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism - GlobeNewsWire